Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review
Purpose Hormone therapy with Tamoxifen is an effective treatment that can decrease recurrence rate and mortality. Numerous molecular mechanisms can modify the response to Tamoxifen. The objective of this study was to determine Tamoxifen efficacy on patients’ recurrence and mortality rates, according to the human epidermal growth factor receptor 2 (HER2) status. Methods In this meta-analysis of published studies, relapse and death rates were measured in both HER2 negative and positive patients treated with Tamoxifen. Besides, the relative risk of treatment with Tamoxifen compared to no Tamoxifen treatment was evaluated in both HER2 positive and negative patients. Results There was an increased risk of recurrence in HER2 positive patients who received Tamoxifen compared with HER2 negative ones (RR = 1.63, p value < 0.001). Tamoxifen treatment is associated with decreased relapse rate (RR = 0.70, p value < 0.001); however, it did not effect on HER2 positive ones (RR = 1, p value = 0.99). Conclusion According to the analysis result, the relapse rate in breast cancer patients who were treated with Tamoxifen depends on the HER2 situation. Despite the limited sample size, it is revealed that Tamoxifen can decrease the relapse rate only in HER2 negative patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Pharmacological reports - 73(2021), 2 vom: 07. März, Seite 435-442 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mansouri, Sepideh [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| doi: |
10.1007/s43440-021-00237-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR043617875 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043617875 | ||
| 003 | DE-627 | ||
| 005 | 20230519193343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210326s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s43440-021-00237-z |2 doi | |
| 035 | |a (DE-627)SPR043617875 | ||
| 035 | |a (DE-599)SPRs43440-021-00237-z-e | ||
| 035 | |a (SPR)s43440-021-00237-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Mansouri, Sepideh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating human epidermal growth factor receptor 2 roles in the efficacy of Tamoxifen treatment in breast cancer, a systematic review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose Hormone therapy with Tamoxifen is an effective treatment that can decrease recurrence rate and mortality. Numerous molecular mechanisms can modify the response to Tamoxifen. The objective of this study was to determine Tamoxifen efficacy on patients’ recurrence and mortality rates, according to the human epidermal growth factor receptor 2 (HER2) status. Methods In this meta-analysis of published studies, relapse and death rates were measured in both HER2 negative and positive patients treated with Tamoxifen. Besides, the relative risk of treatment with Tamoxifen compared to no Tamoxifen treatment was evaluated in both HER2 positive and negative patients. Results There was an increased risk of recurrence in HER2 positive patients who received Tamoxifen compared with HER2 negative ones (RR = 1.63, p value < 0.001). Tamoxifen treatment is associated with decreased relapse rate (RR = 0.70, p value < 0.001); however, it did not effect on HER2 positive ones (RR = 1, p value = 0.99). Conclusion According to the analysis result, the relapse rate in breast cancer patients who were treated with Tamoxifen depends on the HER2 situation. Despite the limited sample size, it is revealed that Tamoxifen can decrease the relapse rate only in HER2 negative patients. | ||
| 650 | 4 | |a HER2 status |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Death rate |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Relapse rate |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Tamoxifen |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Breast cancer |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mokhtari-Hesari, Parisa |e verfasserin |4 aut | |
| 700 | 1 | |a Naghavi-al-Hosseini, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Seyednejad, Seyed Afshin |e verfasserin |4 aut | |
| 700 | 1 | |a Majidzadeh-A, Keivan |e verfasserin |4 aut | |
| 700 | 1 | |a Moradi-kalbolandi, Shima |e verfasserin |4 aut | |
| 700 | 1 | |a Ghahremanlou, Marziyeh |e verfasserin |4 aut | |
| 700 | 1 | |a Farahmand, Leila |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological reports |d Heidelberg : Springer Nature, 1998 |g 73(2021), 2 vom: 07. März, Seite 435-442 |w (DE-627)SPR038875861 |w (DE-600)2129019-2 |x 2299-5684 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:2 |g day:07 |g month:03 |g pages:435-442 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s43440-021-00237-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 2 |b 07 |c 03 |h 435-442 | ||